Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint

Bionomics Limited BNOX announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD).
The trial enrolled 151 adult patients. The primary endpoint, measured by the change from baseline to the average of the Subjective Units of Distress Scale (SUDS) scores during a 5-minute Public Speaking Challenge, was not met in the BNC210-treated patients when compared to placebo.
SUDS is a tool for quantifying the intensity of anxiety, fear, or distress on a scale from 0 to 100, with 0 indicating no distress and 100 representing the highest level.
The findings indicate a consistent trend toward improvements across primary and secondary endpoints and a favorable safety and tolerability profile.
The company is continuing its analysis of the PREVAIL dataset and is assessing the next steps for developing BNC210 in SAD.
The company is conducting a Phase 2b ATTUNE Study in PTSD with topline data expected mid-2023.
The company said that its cash position would deliver these milestones and continue operations to at least mid-2024.
Price Action: BNOX shares closed at $6.80 on Friday.